×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
LQDA – liquidia corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
LQDA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/10
08:49 am
lqda
Liquidia Co. (NASDAQ: LQDA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $25.00 price target on the stock.
Low
Report
Liquidia Co. (NASDAQ: LQDA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $25.00 price target on the stock.
4/1
10:33 am
lqda
UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
Low
Report
UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
4/1
08:00 am
lqda
Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
Low
Report
Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
3/28
08:13 pm
lqda
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder [Yahoo! Finance]
Low
Report
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder [Yahoo! Finance]
3/28
09:30 am
lqda
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder
Low
Report
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder
3/27
08:00 am
lqda
Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference
Low
Report
Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference
3/26
01:07 pm
lqda
Liquidia Co. (NASDAQ: LQDA) had its "outperform" rating re-affirmed by analysts at Scotiabank.
Low
Report
Liquidia Co. (NASDAQ: LQDA) had its "outperform" rating re-affirmed by analysts at Scotiabank.
3/20
11:47 am
lqda
Liquidia Co. (NASDAQ: LQDA) had its price target raised by analysts at Scotiabank from $30.00 to $34.00. They now have a "sector outperform" rating on the stock.
Low
Report
Liquidia Co. (NASDAQ: LQDA) had its price target raised by analysts at Scotiabank from $30.00 to $34.00. They now have a "sector outperform" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/28
04:30 pm
lqda
Form 8-K Liquidia Corp For: Mar 28
Low
Report
Form 8-K Liquidia Corp For: Mar 28
3/19
06:46 am
lqda
Form 10-K Liquidia Corp For: Dec 31
Low
Report
Form 10-K Liquidia Corp For: Dec 31
3/19
06:38 am
lqda
Form 8-K Liquidia Corp For: Mar 19
Low
Report
Form 8-K Liquidia Corp For: Mar 19
3/18
08:15 am
lqda
Form 8-K Liquidia Corp For: Mar 17
Low
Report
Form 8-K Liquidia Corp For: Mar 17
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/26
Liquidia Technologies Inc (NASDAQ: LQDA) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $37.00 price target on the stock.
43.5%
4/3 Form 4 Liquidia Technologies For: Apr 01 Filed by: Eshelman Ventures, LLC 25.0%
1/10 Form 4 Liquidia Technologies For: Dec 27 Filed by: Canaan VIII LP 22.5%
4/7 Form 4 Liquidia Technologies For: Apr 03 Filed by: Eshelman Ventures, LLC 17.1%
1/15 Liquidia Technologies Inc (NASDAQ: LQDA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.25 price target on the stock. 14.0%
12/24 Liquidia Technologies Announces $22.4 Million Private Placement 12.5%
8/8 Q2/2019 6/30/2019 EPS -0.320 ZacksConsensus -0.570 ActVsEst 0.250 - Beat 9.6%
11/13 Q3/2019 9/30/2019 EPS -0.720 ZacksConsensus -0.520 ActVsEst (0.200) - Miss 8.5%
8/23 Form S-3 Liquidia Technologies 7.8%
3/20 Form 8-K Liquidia Technologies For: Mar 18 7.5%
4/3 Form 4 Liquidia Technologies For: Apr 01 Filed by: Eshelman Ventures, LLC 25.0%
1/10 Form 4 Liquidia Technologies For: Dec 27 Filed by: Canaan VIII LP 22.5%
4/7 Form 4 Liquidia Technologies For: Apr 03 Filed by: Eshelman Ventures, LLC 17.1%
1/15 Liquidia Technologies Inc (NASDAQ: LQDA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.25 price target on the stock. 14.0%
12/24 Liquidia Technologies Announces $22.4 Million Private Placement 12.5%
8/8 Q2/2019 6/30/2019 EPS -0.320 ZacksConsensus -0.570 ActVsEst 0.250 - Beat 9.6%
11/13 Q3/2019 9/30/2019 EPS -0.720 ZacksConsensus -0.520 ActVsEst (0.200) - Miss 8.5%
8/23 Form S-3 Liquidia Technologies 7.8%
3/20 Form 8-K Liquidia Technologies For: Mar 18 7.5%
TOP News Decliners
9/3
Liquidia to Present at H.C. Wainwright Healthcare Conference
-18.6%
8/26 Form 4 Liquidia Technologies For: Aug 22 Filed by: Albury Timothy -17.6%
4/20 Form SEC STAFF LETTER Liquidia Technologies -14.8%
11/6 Liquidia to Report Third Quarter 2019 Financial Results and Provide Corporate Update on November 13, 2019 -14.6%
2/26 Liquidia to Present at Cowen 40th Annual Health Care Conference -13.3%
12/31 Liquidia Technologies Inc (NASDAQ: LQDA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -11.1%
4/30 Liquidia Releases Final LIQ861 Results from Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension -9.9%
1/24 Liquidia Announces Poster Presentation at the 14th Annual World Congress of the Pulmonary Vascular Research Institute (PVRI) -8.8%
6/5 Liquidia Announces Clinical Update on INSPIRE; Targeting NDA Filing for LIQ861 in Late 2019 -8.4%
4/8 Liquidia Technologies Inc (NASDAQ: LQDA) had its price target raised by analysts at Wedbush from $37.00 to $41.00. They now have an "outperform" rating on the stock. -8.3%
8/26 Form 4 Liquidia Technologies For: Aug 22 Filed by: Albury Timothy -17.6%
4/20 Form SEC STAFF LETTER Liquidia Technologies -14.8%
11/6 Liquidia to Report Third Quarter 2019 Financial Results and Provide Corporate Update on November 13, 2019 -14.6%
2/26 Liquidia to Present at Cowen 40th Annual Health Care Conference -13.3%
12/31 Liquidia Technologies Inc (NASDAQ: LQDA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -11.1%
4/30 Liquidia Releases Final LIQ861 Results from Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension -9.9%
1/24 Liquidia Announces Poster Presentation at the 14th Annual World Congress of the Pulmonary Vascular Research Institute (PVRI) -8.8%
6/5 Liquidia Announces Clinical Update on INSPIRE; Targeting NDA Filing for LIQ861 in Late 2019 -8.4%
4/8 Liquidia Technologies Inc (NASDAQ: LQDA) had its price target raised by analysts at Wedbush from $37.00 to $41.00. They now have an "outperform" rating on the stock. -8.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: